Michael N. Hall
University of Basel
371 Papers
2.5K Citations
Michael N. Hall is an academic researcher from University of Basel. The author has contributed to research in topics: Biology & Medicine. The author has an hindex of 107, co-authored 312 publications. Previous affiliations of Michael N. Hall include Wellcome Trust Sanger Institute & Umeå University.
Chat about Author
Papers
TOR signaling in growth and metabolism.
TL;DR: The physiological consequences of mammalianTORC1 dysregulation suggest that inhibitors of mammalian TOR may be useful in the treatment of cancer, cardiovascular disease, autoimmunity, and metabolic disorders.
6K
Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive
Estela Jacinto,Robbie Loewith,Anja Schmidt,Shuo Lin,Markus A. Rüegg,Alan Hall,Michael N. Hall +6 more
TL;DR: Two distinct TOR complexes constitute a primordial signalling network conserved in eukaryotic evolution to control the fundamental process of cell growth.
2.2K
TOR, a Central Controller of Cell Growth
Tobias Schmelzle,Michael N. Hall +1 more
TL;DR: Findings reveal that the target of rapamycin TOR controls an unusually abundant and diverse set of readouts all of which are important for cell growth, suggesting that this conserved kinase is such a central regulator.
2.1K
Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast.
TL;DR: Nonallelic noncomplementation between FPR1, TOR1, and TOR2 alleles suggests that the products of these genes may interact as subunits of a protein complex that may mediate nuclear entry of signals required for progression through the cell cycle.
2K
Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control
Robbie Loewith,Estela Jacinto,Stephan Wullschleger,Anja Lorberg,José L. Crespo,Debora Bonenfant,Wolfgang Oppliger,Paul Jenoe,Michael N. Hall +8 more
TL;DR: Two functionally distinct TOR complexes account for the diversity, specificity, and selective rapamycin inhibition of TOR signaling.
1.9K